Royalty Pharma plc
RPRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Royalty Pharma plc (RPRX) is listed under Biotechnology. Valued at $31.10B, RPRX is a large-cap name in its sector. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Market Cap
$31.10B
Beta
0.40
P/E (TTM)
28.43
P/E (Fwd)
9.62
EPS (TTM)
$1.90
EPS (Fwd)
$5.61
ROE
13.8%
ROA
5.5%
Cash
$608.3M
Total Debt
$8.97B
Free CF
-$980.3M
52W Change
61.5%
Annual Financials
Cash vs Debt
Royalty Pharma plc carries $8.97B in total debt against $608.3M in cash reserves — debt is roughly 14.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$980.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 13.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $2.24B (2022) to $2.38B (2025).
The relatively low beta of 0.40 suggests RPRX is a less volatile holding compared to the broader index. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Royalty Pharma plc and its sector.